Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers

NCT05117554 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.

NCT NCT05117554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05117554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers
Lead sponsor
Arcus Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 9, 2021
Completion date
February 17, 2023
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants